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This study identified possible prognostic signs in the acute stage of Vogt-Koyanagi-Harada (VKH) disease
in a retrospective chart review of all patients diagnosed with VKH disease between 1991 and 2001. Those
who were diagnosed more than 1 month after the onset of ocular symptoms were excluded. Data recorded
included age, sex, clinical features, systemic manifestations, recurrence, treatment, complications, and final
visual acuity. Exudative retinal detachment was ranked into 3 grades (grade 1: within peripapillary 3 disc
diameters and arcade; grade 2: larger than grade 1 but no inferior retinal detachment; grade 3: inferior
or total retinal detachment). Of the 31 patients, 19 were males and 12 were females. Mean age at presentation
was 38.55 ( 10.63 years. The mean follow-up period was 33.09 months. Extraocular manifestations were
present in 17 cases. Four patients had at least one complication, including cataract in seven eyes and
glaucoma in one eye. Forty-nine eyes (79%) had a final visual acuity of 6/12 or better. Final visual acuity
was significantly better in younger patients (p = 0.023) and those who had less extensive retinal detachment
(p = 0.006), no pigmentary change (p = 0.008) and no complications (p = 0.030). The visual prognosis of
VKH disease is variable, though generally favorable. In the acute stage, the extent of retinal detachment
may be an important risk factor for visual outcome. Further study of this factor as an indicator for treatment
is necessary.
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Vogt-Koyanagi-Harada (VKH) disease is a chronic bilateral
granulomatous panuveitis with involvement of the central
nervous system and auditory and integumentary systems
[1,2]. The exact cause of the disease is uncertain, but T-
lymphocyte-mediated autoimmunity directed against
melanocytes is likely to play an important role [3–6]. There
seems to be a genetic predisposition, because specific hu-
man leukocyte antigen (HLA) types have been reported to
be associated with the disease [7–11]. VKH disease is more
prevalent in certain racial and ethnic groups, particularly in
Asian individuals and certain Latin-American groups [1,
12–14]. The visual prognosis is generally favorable, yet
significant vision loss occurs in some cases. Irreversible
vision loss is typically caused by complications that arise as
a result of the disease or its treatment, including cataract,
glaucoma, choroidal neovascularization, and subretinal
fibrosis. A number of factors are reported to be related to
these complications, such as age at onset, worse visual
acuity at presentation, rapid tapering of steroid, and interval
between symptom onset and diagnosis [15–22]. It would be
helpful to find prognostic factors in the early stage of VKH
disease that could be used as a treatment guideline. In this
study, we tried to identify possible prognostic factors in the
early stage of VKH disease.
MATERIALS AND METHODS
We performed a retrospective chart review of all patients di-
agnosed with VKH disease in our ophthalmic departments
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between 1991 and 2001. Diagnosis of VKH disease is based
on the features typically present at the stage of disease
during which the patients are examined; other uveitis con-
ditions are excluded by history, examination, and ancil-
lary testing. The revised criteria for VKH disease were
applied retrospectively to patients with a diagnosis of
endogenous uveitis [23]. Patients who were diagnosed and
treated before visiting our departments or who were fol-
lowed up for less than 6 months were excluded. In order to
catch all ocular signs in the early stage of VKH disease, we
excluded those who visited more than 1 month after the
onset of ocular symptoms.
Charts were reviewed for demographic data, clinical
features, systemic manifestations, recurrence, treatment,
complications, and final visual acuity. Ophthalmologic
examinations included slit lamp biomicroscopy, intra-
ocular pressure, indirect ophthalmoscopy, contact lens
biomicroscopy, and fundus fluorescein angiography. A
cataract was defined as any change in the normally clear
media of the native lens that resulted in loss of vision,
caused a change in refractive error, or obscured visuali-
zation of the fundus. Glaucoma was defined as a sustained
elevation of the intraocular pressure necessitating the use of
medical and/or surgical therapy. Choroidal neovasculari-
zation was defined as growth of new blood vessels within
the subretinal space or subretinal pigment epithelial space,
as demonstrated by fluorescein angiography. Although not
previously reported, exudative retinal detachment was
empirically ranked into one of three grades (grade 1: within
peripapillary 3 disc diameters and arcade; grade 2: larger
than grade 1 but no inferior retinal detachment; grade 3:
inferior or total retinal detachment) (Figures 1–3).
Statistical analysis
The Chi-squared test was used to compare the proportions
between two or three groups. Fisher’s exact test was used
when one or more expected values were less than 5 in the
2 = 2 tables. If sample variances were comparable, sam-
ple means between two or three groups were compared
using a t test or one-way ANOVA. If sample variances
were not comparable, sample mean ranks between two
groups were compared using the Mann-Whitney U test.
RESULTS
There were 31 patients with mean age at presentation of
38.55 (  10.63 years (range, 20–63 years); 19 (61.3%) were
male. The mean follow-up period was 33.09 months. At
Figure 1. A 28-year-old male diagnosed with Vogt-Koyanagi-Harada
disease 2 days after onset of ocular symptoms. There were no central
nervous system or integumentary symptoms. Ophthalmic manifesta-
tions included a silent anterior chamber and grade 1 exudative retinal
detachment in both eyes. The final visual acuity was 6/6 after treatment.
No complications developed during follow-up.
Figure 2. A 51-year-old female, with prodromal central nervous system
symptoms, diagnosed with Vogt-Koyanagi-Harada disease 3 days after
the onset of ocular symptoms. Ophthalmic manifestations included ante-
rior uveitis and grade 2 exudative retinal detachment in both eyes. The
final visual acuity was 6/6.7 after treatment. No complications developed
during follow-up.
initial presentation, ocular manifestations were usually
symmetrical in both eyes. Anterior uveitis was present in 12
cases (38.7%), vitreous haziness in 15 (48.4%), exudative
retinal detachment in 31 (100%), and neurologic or auditory
manifestations in 16 (51.6%). The extent of exudative retinal
detachment did not correlate with interval between symp-
tom onset and diagnosis (p = 0.172, Spearman’s rank cor-
relation test). At the time of the last follow-up, cutaneous
manifestations were present in one patient (3.2%) and sun-
set glow fundus or other ocular depigmentation in 22
eyes. Overall, four patients (7 eyes) developed cataracts and
one developed glaucoma (1 eye with both cataract and
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Twenty-seven patients were diagnosed and treated
within 2 weeks after the onset of ocular symptoms, while
four patients were diagnosed and treated between 2 weeks
and 1 month. Treatment consisted of oral corticosteroid
(1 mg/kg/day) and topical steroid eye drops in 17 patients,
and megadose methylprednisolone (250 mg intrave-
nously every 6 hours for 3 days) plus oral and topical ste-
roid in 14 patients. Corticosteroid was tapered gradually
over 6 months. Cytotoxic agents were used as adjuvant
therapy in three cases that responded poorly to corticoste-
roid. After treatment, recurrence occurred in seven patients
(22.6%). Forty-nine eyes (79%) had a final visual acuity of
6/12 or better.
Among patients treated within 1 month of the onset of
ocular symptoms, those with extraocular manifestations
had a significantly longer interval between symptom onset
and treatment than those without (p = 0.007). There were no
significant differences in age and gender distribution,
recurrence, ophthalmic features, presence of complications,
or final visual acuity between these two groups (Table 1).
For patients who developed complications, there were no
Figure 3. A 51-year-old male diagnosed with Vogt-Koyanagi-Harada
disease 1 week after onset of ocular symptoms. There were no central
nervous system or integumentary symptoms. Ophthalmic manifesta-
tions included mild vitreous cell reaction and grade 3 exudative retinal
detachment in both eyes. The final visual acuity was 6/30 after treatment.
There was one recurrence during follow-up. The fundus had a sunset
glory appearance in both eyes at the last visit.
glaucoma); no choroidal neovascularization was found at
the last follow-up.
Table 1. Characteristics of patients with and without extraocular manifestations
With extraocular manifestation Without extraocular manifestation p
(n = 17) (n = 14)
Mean age (  SD, yr 40.47 (  10.95 36.21 (  10.12 0.274*
Gender 0.138†
Male, n (%) 8 (47.1) 11 (78.6)
Female, n (%) 9 (52.9) 3 (21.4)
Interval between symptom 1.70 (  1.50 0.76 (  0.71 0.007*
onset and treatment (  SD, wk
Anterior chamber reaction 1.000†
Yes 6 5
No 11 9
Vitreous reaction 0.722†
Yes 9 6
No 8 8
RD grading (  SD 1.88 (  0.78 1.86 (  0.77 0.953*
Recurrence
Yes 4 3
No 13 11
Presence of complications
Cataract 2 2 1.000†
Glaucoma 1 0 1.000†
CNV 0 0
Final visual acuity * 6/12 14 9 0.412†
*Mann-Whitney U test; †Fisher’s exact test. SD = standard deviation; RD = retinal detachment; CNV = choroidal neovascularization.
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Table 2. Factors for the development of complications
Complications No complications p
(n = 4) (n = 27)
Mean age (  SD, yr 37.75 (  13.33 38.67 (  10.47 0.875*
Gender
Male, n (%) 4 (100) 15 (55.6)
Female, n (%) 0 12 (44.4)
Interval between symptom 1.25 (  0.50 1.11 (  0.32 0.657*
onset and treatment (  SD, wk
Anterior chamber reaction 0.630†
Yes 2 9
No 2 18
Vitreous reaction 1.000†
Yes 2 13
No 2 14
RD grading (  SD 2.75 (  0.50 1.74 (  0.71 0.023‡
Extraocular manifestation 1.000†
Yes 2 15
No 2 12
Recurrence 0.028†
Yes 3 4
No 1 23
*t test, unpaired; †Fisher’s exact test; ‡Mann-Whitney U test. SD = standard deviation; RD = retinal detachment.
significant differences in the age and gender distribution,
interval between symptom onset and diagnosis, anterior
uveitis, or extraocular manifestations. The extent of exu-
dative retinal detachment (p = 0.023) and recurrence (p =
0.028) were significantly related to the development of
complications (Table 2). The extent of exudative retinal
detachment was the only significant factor in the
development of recurrence (p = 0.048) (Table 3).
A number of factors were examined in this study to
identify those that were associated with a worse outcome.
The mean age was significantly greater among patients
with final vision worse than 6/12 compared with patients
with final vision of 6/12 or better (p = 0.023) (Table 4). There
was no difference in the gender distribution, irrespective
of the presence of extraocular manifestations. There was
a difference in the incidence of recurrence with visual
outcome, but this did not reach significance (p = 0.056). A
significant difference was detected in patients with the
complication of cataract, though not glaucoma, which might
be due to the limited number of cases. Of the ophthalmic
features in the early stage, anterior chamber reaction and
vitreous reaction were not significantly related to visual
outcome; however, the extent of exudative retinal detach-
ment (p = 0.006) was significantly different between the
group with final vision better than 6/12 and the group
with final vision worse than 6/12. The presence of ocular
pigmentary changes also correlated with poor visual out-
come (p = 0.008) (Table 4). In patients who were diagnosed
and treated within 2 weeks after the onset of ocular symp-
toms, the extent of exudative retinal detachment (p =
0.023) and the presence of ocular pigmentary changes (p =
0.029) were also significantly correlated with visual out-
come (Table 5). Contrary to the data in Table 4, patients
with anterior chamber reaction tended to have a final vision
of 6/12 or better (p = 0.039).
DISCUSSION
Patients with VKH disease may have varied outcome with
regard to final visual acuity. The treatment of choice varies
around the world. Usually, the principles of therapy of
VKH disease are to suppress the initial intraocular
inflammation with early and aggressive use of systemic
corticosteroid therapy. Cytotoxic/immunosuppressive
agents are needed in refractory cases [2]. Most patients
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Table 3. Factors affecting recurrence
Recurrence No recurrence p
(n = 7) (n = 24)
Mean age (  SD, yr 35.14 (  13.93 39.54 (  9.60 0.344*
Gender 0.676†
Male, n (%) 5 (71.4) 14 (58.3)
Female, n (%) 2 (28.6) 10 (41.7)
Interval between symptom 1.14 (  1.28 1.74 (  1.27 0.283*
onset and treatment (  SD, wk
Anterior chamber reaction 1.000†
Yes 3 8
No 4 14
Vitreous reaction 0.685†
Yes 4 11
No 3 13
RD grading (  SD 2.43 (  0.79 1.71 (  0.69 0.048‡
Extraocular manifestation 1.000†
Yes 4 13
No 3 11
*t test, unpaired; †Fisher’s exact test; ‡Mann-Whitney U test. SD = standard deviation; RD = retinal detachment.
respond and regain vision. However, significant vision
loss resulting from complications occurs in spite of inten-
sive treatment [13–15,18]. Treatment without massive
corticosteroid therapy was reported with good visual out-
come [24]. Considering the side effects of massive cortico-
steroid therapy, treatment without it would be useful in
some cases with a benign course. In order to decide which
patient will have a benign course, factors in the acute stage
of VKH disease need to be recognized to guide treatment.
A number of factors are reported to be related to poor
visual outcome, including the presence of complications,
age at onset, worse visual acuity at presentation, rapid
tapering of steroid, interval between symptom onset and
diagnosis, and a greater number of recurrences [15–22]. The
development of complications, recurrence, and tapering of
steroid are not good indicators at an early stage. Age is a
controversial factor. Ohno and associates reported that the
younger the age at disease onset, the worse the final visual
acuity [15]. Tabbara et al also found poor results in pediatric
patients [16]. However, Rathinam et al reported that children
16 years of age or younger with VKH disease generally do
well [17]. In Read et al’s report, a statistically significant
association existed between poor final visual acuity and
greater age at onset. Our data support the suggestion by
Read et al that greater age at onset is associated with poor
visual outcome [18]. In their report, eyes with a better visual
acuity at presentation were more likely to have a better
visual acuity at final follow-up [18]. As usual, early diagno-
sis and prompt treatment is the key to success. Fujioka et
al noted that if patients were not treated within 2 weeks,
longer steroid therapy was required [19]. Mondkar and
associates reported that visual prognosis was good in
patients presenting within 1 month of onset of symptoms
[20]. Bouchenaki et al found that the inflammation was
more easily controlled in patients who were diagnosed in
less than 2 weeks [21]. Since we included only patients who
were diagnosed within 1 month after ocular symptom onset,
the influence of the interval factor could not be evaluated in
this study. However, it seems that interval influenced the
outcome, as some factors differed between patient groups
who were diagnosed within 1 month or within 2 weeks. The
significance of age and complications diminished in patients
who were diagnosed and treated within 2 weeks. This
implies that the earlier patients were treated, the less likely
they were to develop complications, even in the older age
group. Like all other diseases, early diagnosis and prompt
treatment is the key to prevent complications and, hence, to
better outcome.
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Hayasaka et al reported that the VK form of VKH di-
sease (severe anterior uveitis and exudative retinal detach-
ment) was more resistant to treatment, requiring more than
200 mg of intravenous prednisone therapy daily [25]. In
our study, the extent of exudative retinal detachment cor-
related significantly with the development of recurrence or
complications and final visual outcome. Although not
previously reported, we graded the extent of exudative
retinal detachment according to our empirical experience
that patients with less exudative retinal detachment had
better outcome. Our results provide quantitative evidence
to support this speculation. Nevertheless, there was no
significant difference between anterior chamber reaction
and the development of complications or recurrence or
final visual outcome. Moreover, patients diagnosed within
2 weeks with anterior chamber reaction seemed to have
better visual outcome than those with no anterior chamber
reaction. This was contradictory to Hayasaka et al’s report.
We cannot explain the discrepancy in the influence of
anterior chamber reaction between patients diagnosed
within 2 weeks and those diagnosed within 1 month. A
large-scale study is necessary to solve this puzzle.
In conclusion, our study showed that the extent of
exudative retinal detachment might be an important prog-
nostic factor for visual outcome and might be a useful treat-
ment guideline in the early stage of VKH disease.
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Table 4. Factors affecting final visual acuity
Final VA * 6/12 Final VA < 6/12 p
(49 eyes) (13 eyes)
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onset and treatment (  SD, wk
Anterior chamber reaction 0.337†
Yes 20 3
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Vitreous reaction 1.000†
Yes 24 6
No 25 7
RD grading (  SD 1.63 (  0.73 2.31 (  0.75 0.006*
Extraocular manifestation 0.220†
Yes 29 5
No 20 8
Recurrence 0.056†
Yes 8 6
No 41 7
Presence of complications 3 4 0.030†
Cataract 3 4 0.030†
Glaucoma 0 1 0.210†
CNV 0 0
Ocular depigmentation 0.008†
Yes 13 9
No 36 4
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Table 5. Prognostic factors for visual outcome in patients treated early () 2weeks)
Final VA * 6/12 Final VA < 6/12 p
(43 eyes) (11 eyes)
Mean age (  SD, yr 38.28 (  10.96 42.18 (  6.40 0.236*
Gender 0.087†
Male, n (%) 21 (48.8) 9 (81.8)
Female, n (%) 22 (51.2) 2 (18.2)
Anterior chamber reaction 0.039†
Yes 18 1
No 25 10
Vitreous reaction 0.736†
Yes 20 4
No 23 7
RD grading (  SD 1.60 (  0.69 2.18 (  0.75 0.023*
Extraocular manifestation 0.095†
Yes 25 3
No 18 8
Recurrence 0.185†
Yes 6 4
No 37 7
Presence of complications 3 2 0.266†
Cataract 3 2 0.266†
Glaucoma 0 1 0.204†
CNV 0 0
Ocular depigmentation 0.029†
Yes 11 7
No 32 4
*Mann-Whitney U test; †Fisher’s exact test. VA = visual acuity; SD = standard deviation; RD = retinal detachment; CNV = choroidal
neovascularization.
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